NEWRON PHARMACEUT. EO-20 - Asset Resilience Ratio
NEWRON PHARMACEUT. EO-20 (NP5) has an Asset Resilience Ratio of 41.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check NEWRON PHARMACEUT. EO-20 (NP5) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how NEWRON PHARMACEUT. EO-20's Asset Resilience Ratio has changed over time. See NP5 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down NEWRON PHARMACEUT. EO-20's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NP5 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €16.68 Million | 41.67% |
| Total Liquid Assets | €16.68 Million | 41.67% |
Asset Resilience Insights
- Very High Liquidity: NEWRON PHARMACEUT. EO-20 maintains exceptional liquid asset reserves at 41.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
NEWRON PHARMACEUT. EO-20 Industry Peers by Asset Resilience Ratio
Compare NEWRON PHARMACEUT. EO-20's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for NEWRON PHARMACEUT. EO-20 (2009–2025)
The table below shows the annual Asset Resilience Ratio data for NEWRON PHARMACEUT. EO-20.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.67% | €16.68 Million ≈ $19.50 Million |
€40.03 Million ≈ $46.80 Million |
+37.14pp |
| 2024-12-31 | 4.53% | €2.89 Million ≈ $3.38 Million |
€63.91 Million ≈ $74.72 Million |
-19.68pp |
| 2023-12-31 | 24.21% | €6.26 Million ≈ $7.32 Million |
€25.87 Million ≈ $30.24 Million |
-0.93pp |
| 2022-12-31 | 25.14% | €9.35 Million ≈ $10.93 Million |
€37.20 Million ≈ $43.48 Million |
+6.17pp |
| 2021-12-31 | 18.97% | €9.57 Million ≈ $11.19 Million |
€50.49 Million ≈ $59.02 Million |
-16.26pp |
| 2020-12-31 | 35.23% | €18.04 Million ≈ $21.09 Million |
€51.20 Million ≈ $59.86 Million |
+6.85pp |
| 2019-12-31 | 28.38% | €17.11 Million ≈ $20.00 Million |
€60.29 Million ≈ $70.48 Million |
+1.33pp |
| 2018-12-31 | 27.05% | €16.23 Million ≈ $18.97 Million |
€60.00 Million ≈ $70.15 Million |
+0.43pp |
| 2017-12-31 | 26.62% | €19.44 Million ≈ $22.73 Million |
€73.02 Million ≈ $85.37 Million |
+20.40pp |
| 2016-12-31 | 6.22% | €3.52 Million ≈ $4.12 Million |
€56.59 Million ≈ $66.16 Million |
-4.87pp |
| 2015-12-31 | 11.09% | €4.92 Million ≈ $5.75 Million |
€44.38 Million ≈ $51.88 Million |
-7.65pp |
| 2014-12-31 | 18.74% | €6.95 Million ≈ $8.12 Million |
€37.07 Million ≈ $43.34 Million |
+1.48pp |
| 2013-12-31 | 17.26% | €5.46 Million ≈ $6.38 Million |
€31.62 Million ≈ $36.96 Million |
+9.10pp |
| 2012-12-31 | 8.16% | €3.64 Million ≈ $4.26 Million |
€44.65 Million ≈ $52.20 Million |
+4.30pp |
| 2009-12-31 | 3.85% | €1.60 Million ≈ $1.88 Million |
€41.68 Million ≈ $48.73 Million |
-- |
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more